Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosisA case report and review of the literature

被引:12
作者
Brown, Paula [1 ]
Jay, Richard [2 ]
Fox, Andrea [1 ]
Oliver, Matthew [3 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Pharm, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook Hlth Sci Ctr, Dept Med Hematol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Med Nephrol, Toronto, ON M4N 3M5, Canada
关键词
Heparin-induced thrombocytopenia; HIT; fondaparinux; Arixtra; hemodialysis; extracorporeal circuit thrombosis; ANTICOAGULANT; THERAPY;
D O I
10.1111/hdi.12003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening condition that can develop after exposure to unfractionated or low-molecular-weight heparins. Treatment options appear to be limited in patients on concurrent intermittent hemodialysis. We report the case of an 88-year-old man newly initiated on high-flux hemodialysis who developed HIT and extracorporeal circuit thrombosis after 3 weeks of exposure to unfractionated heparin. Our patient was successfully treated with fondaparinux 2.5mg subcutaneously three times per week and citrate during dialysis sessions. Antifactor Xa levels were measured on several occasions while receiving fondaparinux.
引用
收藏
页码:444 / 449
页数:6
相关论文
共 18 条
[1]  
Bermejo N, 2007, J THROMB HAEMOST, V5, pP
[2]   Laboratory monitoring of new anticoagulants [J].
Castellone, Donna D. ;
Van Cott, Elizabeth M. .
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (03) :185-187
[3]  
Davenport Andrew, 2004, Hemodial Int, V8, P295, DOI 10.1111/j.1492-7535.2004.01108.x
[4]   Antibodies to Heparin-Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis [J].
Davenport, Andrew .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (02) :361-374
[5]   Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia [J].
Efird, Leigh E. ;
Kockler, Denise R. .
ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) :1383-1387
[6]  
Fischer Karl-Georg, 2007, Hemodial Int, V11, P178, DOI 10.1111/j.1542-4758.2007.00166.x
[7]  
Fischer KG, 2007, HEPARIN INDUCED THRO, P510
[8]   Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis [J].
Greinacher, A ;
Zinn, S ;
Wizemann ;
Birk, UW .
LANCET, 1996, 348 (9029) :764-764
[9]   Use of fondaparinux (ARIXTRA®) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II [J].
Haase, M ;
Bellomo, I ;
Rocktaeschel, J ;
Ziemer, S ;
Kiesewetter, H ;
Morgera, S ;
Neumayer, HH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (02) :444-446
[10]   Parenteral anticoagulants [J].
Hirsh, Jack ;
Bauer, Kenneth A. ;
Donati, Maria B. ;
Gould, Michael ;
Samama, Meyer M. ;
Weitz, Jeffrey I. .
CHEST, 2008, 133 (06) :141S-159S